ACT+EEG
Diagnostic TestCombination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
NCT Number: NCT04943562
This study aims to evaluate the viability of the combined use of wearable and portable technologies for sleep staging. The results will be compared with polysomnography, in order to achieve clinical and diagnostic validation. Three domains of devices will be used: Movement sensors, wearable EEG band and smartphones
The project will be composed of two stages:
In the first stage, the use of the combination of actigraphy and EEG will be used for sleep staging in a sample of 12 healthy volunteers from 20 to 80 years old, both genders and with no sleep disorders for each combination of ACT+EEG. Considering there will two of each (thus four combinations), the final sample will be composed of 48 individuals. Once recruited, evaluated according to the inclusion and exclusion criteria and consented with the terms of this study, the participants will be referred to the sleep lab, in which they will undergo a full night type-1 in lab polysomnography, following the setup recommended by the American Academy of Sleep Medicine. Concomitantly with the polysomnography, the participants will also use the combination of ACT+EEG.
In the second stage, the most successful combination tested in the first stage will be tested in a clinical sample, composed by 60 participants from both genders, from 20 to 80 years old and with at least one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia, 30% should have high risk to sleep apnea and 70% should have excessive sleepiness scale. All the procedures, including the polysomnography will be performed identically to the first step.
Interested in participating?
Request Info20 year–80 year
All sexes
Observational
SleepUp Tecnologia em Saúde LTDA, São Caetano do Sul, São Paulo, Brazil
This study aims to evaluate the viability of the combined use of wearable and portable technologies for sleep staging. The results will be compared with polysomnography, in order to achieve clinical and diagnostic validation. Three domains of devices will be used:
The project will be composed of three stages:
In the first stage, the use of the combination of actigraphy and EEG will be used for sleep staging in a sample of 12 healthy volunteers from 20 to 80 years old, both genders and with no sleep disorders for each combination of ACT+EEG. Considering there will two of each (thus four combinations), the final sample will be composed of 48 individuals. Once recruited, evaluated according to the inclusion and exclusion criteria and consented with the terms of this study, the participants will be referred to the sleep lab, in which they will undergo a full night type-1 in lab polysomnography, following the setup recommended by the American Academy of Sleep Medicine. Concomitantly with the polysomnography, the participants will also use the combination of ACT+EEG.
In the second stage, the most successful combination tested in the first stage will be tested in a clinical sample, composed by 60 participants from both genders, from 20 to 80 years old and with at least one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia (as measured by the insomnia severity index), 30% should have high risk to sleep apnea (as measured by the STOP-BANG questionnaire) and 70% should have excessive sleepiness scale (as measured by the Epworth sleepiness scale). All the procedures, including the polysomnography will be performed identically to the first step.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
FIRST STAGE (Healthy volunteers)
Inclusion criteria
Exclusion criteria
SECONDS STAGE (volunteers with sleep disorders or complaints)
Inclusion criteria
Exclusion criteria
Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
Time frame: Immediately after the polysomnography.
Time from the beginning of the polysomnographic record until the first epoch of sleep.
Time frame: Immediately after the polysomnography.
Total time of epochs staged as sleep.
Time frame: Immediately after the polysomnography.
Percentage of sleep in relation to total record/bed time.
Time frame: Immediately after the polysomnography.
Total time of epochs staged as "wake" after sleep latency.
Time frame: Immediately after the polysomnography.
Time from sleep latency until the first epoch of REM sleep.
Time frame: Immediately after the polysomnography.
Time corresponding to epochs staged as each of the sleep stages (N1, N2, N3 and REM)
Time frame: Immediately after the polysomnography.
Percentage corresponding to epochs staged as each of the sleep stages (N1, N2, N3 and REM), in comparison with total sleep time.
Contact information is provided by the study sponsor or research team.
Renata Bonaldi, PhD
CONTACT
Renata Bonaldi, PhD
CONTACT
SleepUp Tecnologia em Saúde Ltda
Industry
Evaluation of the Viability of Actigraphy, Wearable EEG Band and Smartphone for Sleep Staging in Comparison With Polysomnography
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05276362
Apnea, Dyssomnias
Menlo Park, California, United States
View Trial DetailsNCT03946228
Apnea, Behavior
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05663034
Behavior, Behavioral Symptoms
Eglin Air Force Base, Florida, United States
View Trial DetailsNCT05393830
Behavior, Dyssomnias
Boston, Massachusetts, United States
View Trial Details